A multicenter, randomized, double-blind, placebo-controlled clinical study to evaluate the efficacy and safety of Tongluo Mingmu Capsules in the treatment of non-proliferative diabetic retinopathy

Authors
Category Primary study
Registry of TrialsChinese Clinical Trial Register
Year 2026
INTERVENTION: Control group: Tongluo Mingmu Capsule placebo:placebo;Experimental group: Tongluo Mingmu Capsule:Tongluo Mingmu Capsule; CONDITION: Non‐Proliferative Diabetic Retinopathy PRIMARY OUTCOME: DRSS grade; INCLUSION CRITERIA: 1.Age: 18‐70 years (inclusive); 2.At least one eye diagnosed with non‐proliferative diabetic retinopathy caused by type 2 diabetes; 3.Having received stable glycemic control treatment for at least 12 weeks; 4.The subject voluntarily signs the informed consent form;
Epistemonikos ID: dc260f02ca7e9a60574aa49bd698fbedbc76bffb
First added on: Mar 07, 2026